The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials
- 6 April 2019
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 18 (6), 576-582
- https://doi.org/10.1016/j.autrev.2018.12.008
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registryAnnals Of The Rheumatic Diseases, 2012
- Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical TrialPLOS ONE, 2012
- Signaling and ligand interaction of ILT7: receptor‐mediated regulatory mechanisms for plasmacytoid dendritic cellsImmunological Reviews, 2010
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory CellsImmunity, 2009
- Etanercept in Sjögren's syndrome: A twelve‐week randomized, double‐blind, placebo‐controlled pilot clinical trialArthritis & Rheumatism, 2004
- Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)Arthritis & Rheumatism, 2004
- Cathepsin S inhibitor prevents autoantigen presentation and autoimmunityJCI Insight, 2002
- Elevated tear interleukin-6 levels in patients with Sjögren syndromeOphthalmology, 1998